Bruce Myers, CFO of Pharmacopeia, will step down ”to pursue other opportunities” in May, following the company’s annual stockholders’ meeting. The Princeton, NJ-based parent company of Accelrys recently ended a dispute between key stockholders and company officials over the proposed acquisition of Eos Biotechnology, which stockholders ultimately voted against. It was not clear what role this played in Myers’ departure. Pharmacopeia will also lose John Baldwin, chief science and technology officer, who will retire at the end of this month.
Maynard, Mass.-based OmniViz has added Cynthia Eades to its staff in the newly created position of chief financial officer and treasurer. Eades joins the company from Webhire, a recruiting software company, where she managed the company’s initial public offering.
Michael Haydock has resigned as president and CEO of Cray, “due to differences with the board of directors in how to restore the company to long-term industry leadership,” according to the company. Haydock, who joined Cray in October from IBM, also stepped down from its board of directors. James Rottsolk, formerly president and CEO, has resumed those duties. Rottsolk listed selling the Cray SV1ex system, “particularly into the growing bioinformatics market,” among his goals.
OSI Pharmaceuticals of Melville, NY, has named Gary Clark senior director of biostatistics and data management. Clark will oversee biostatistics and data management for OSI’s oncology candidates. Prior to joining OSI, Clark was a professor of medicine at Baylor College of Medicine.